SYRE

Spyre Therapeutics announced presentations of clinical and preclinical data for its three IBD antibodies (SPY001, SPY002, and SPY003) at UEGW 2026 in Barcelona. The company presented efficacy and safety data for these half-life extended antibodies in moderately to severely active ulcerative colitis, along with preclinical evidence showing additive efficacy of combination approaches. The SKYLINE study is testing these candidates as monotherapies and pairwise combinations, with combination results expected in 2027.

Spyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026.